PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations
by Zacks Equity Research
Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.
PerkinElmer (PKI) Q1 Earnings Surpass Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.02% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Revvity (PKI) This Earnings Season?
by Zacks Equity Research
Revvity (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Waters (WAT) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of -4.23% and 1.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Finding Top Computer & Tech Stocks: Zacks May Strategy
by John Blank
The Info Tech sector remains a key 2023 returns source. In turn, using the Price to Sales forward 12-month stock valuation ratio is helpful to identify top Computer and Technology stocks.
McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
PerkinElmer (PKI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 16.36% and 7.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will PerkinElmer (PKI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UBER Set to Report Q1 Earnings: Here's What You Should Know
by Zacks Equity Research
The Delivery unit is likely to have aided UBER's Q1 performance.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.
PerkinElmer (PKI) Completes Divestment, New Business Name in Q2
by Zacks Equity Research
PerkinElmer (PKI) completes separation of its businesses into two entities ¿¿¿ the AES business, and the Life Sciences and Diagnostics business.
PerkinElmer's (PKI) Latest Launch to Boost Research Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.
PerkinElmer's (PKI) Q4 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, more than offset by lower COVID-related sales.
PerkinElmer (PKI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.41% and 1.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business, and informatics franchise.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.
Zacks Industry Outlook Highlights Mettler-Toledo, PerkinElmer and Waters
by Zacks Equity Research
Mettler-Toledo, PerkinElmer and Waters have been highlighted in this Industry Outlook article.
3 Instruments Stocks to Watch From a Challenging Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand despite lingering effects of COVID-19.
Why Is PerkinElmer (PKI) Up 10.3% Since Last Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.
PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health
by Zacks Equity Research
PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.
PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.